| Literature DB >> 36161169 |
Mylène Duivon1, Joy Perrier1, Carine Segura-Djezzar2,3, Florence Joly2,3,4,5, Stéphane Rehel1, Christian Berthomier6, Jean-Michel Grellard2, Bénédicte Clarisse2, Julien Geffrelot2,3, George Emile2,3, Christelle Lévy2,3, Fausto Viader1, Francis Eustache1, Béatrice Desgranges1, Géraldine Rauchs1, Bénédicte Giffard1,5.
Abstract
Background: Previous studies have revealed both sleep alterations and prospective memory (PM) impairments in breast cancer (BC) patients. PM refers to memory of intended actions and is crucial for daily living tasks and treatment compliance. As sleep is known to favor memory consolidation, one may expect that changes in sleep quality related to BC would have an impact on PM performance. This study aimed at assessing sleep-dependent consolidation of intentions using an ecological, virtual reality-based PM task in BC patients not treated with chemotherapy. Materials and methods: Thirty-seven early stages BC patients and 21 healthy controls (HC) participated in this study. PM was assessed using a virtual reality task, during which participants learnt a list of intentions and recalled them after a retention interval filled with a day awake or a night of sleep monitored by polysomnography. Sleep spindles and slow waves, brain oscillations involved in sleep-dependent memory consolidation, were quantified automatically using the Aseega software (Physip). Subjective sleep disturbances and markers of quality of life (psychological distress, fatigue, and well-being) were assessed by questionnaires.Entities:
Keywords: breast cancer; cognition; memory consolidation; polysomnography; prospective memory; sleep; virtual reality
Year: 2022 PMID: 36161169 PMCID: PMC9489900 DOI: 10.3389/fnins.2022.908268
Source DB: PubMed Journal: Front Neurosci ISSN: 1662-453X Impact factor: 5.152
Demographic and clinical characteristics of participants (mean ± SD).
| Demographic characteristics | HC ( | BC ( | |
| Age (years) | 62.6 ± 4.4 | 61.8 ± 5.2 | 0.63 |
| Education (years) | 11.8 ± 1.7 | 11.8 ± 3.5 | 0.44 |
| Anxiety (STAI-B) | 42.3 ± 9.3 | 40.8 ± 10.5 | 0.60 |
| Depression (BDI) | 4.1 ± 3.2 | 3.6 ± 3.2 | 0.44 |
|
|
|
| |
| Stage of the cancer, n (%): 0 I IIA | NA | 17 (53%) 12 (38%) 3 (9%) | |
| Tumorectomy, n (%) Mastectomy, n (%) | NA | 29 (91%) 4 (13%) | |
| Time since radiotherapy (months) | NA | 8 ± 2.4 | |
| Treated with endocrine therapy, Not treated with endocrine therapy | NA | 16 (50%) 16 (50%) | |
| Fatigue (FACIT-F) | NA | 36.6 ± 10 | |
| Well-being (FACT-G) | NA | 84.6 ± 17 |
*One patient receiving tumorectomy and mastectomy.
HC, healthy controls; BC, breast cancer; STAI-B, State Trait Anxiety Inventory–Trait; BDI, Beck depression inventory; FACIT-F, Functional Assessment of Chronic Illness Therapy–Fatigue; FACT-G, Functional Assessment of Cancer Therapy–General.
Age, Education, and Depression were compared with Wilcoxon tests and Anxiety with the student’s t.test.
Sleep characteristics, i.e., subjective sleep quality and sleep architecture (mean ± SD).
| Sleep questionnaires | HC ( | BC ( | |||
| Sleep disturbances (PSQI total score) | 5.48 ± 2.8 | 8.29 ± 4.5 |
| ||
| Insomnia severity index (ISI score) | 7.19 ± 4.5 | 11.9 ± 6.6 |
| ||
|
|
|
|
|
|
|
| Total sleep time (min) | 356 ± 68 | 355 ± 68 | 0.001 | 0.97 | < 0.01 |
| Sleep efficiency (%) | 76.9 ± 11 | 74.1 ± 11 | 0.75 | 0.39 | 0.01 |
| Number of awakenings > 1 min | 6.76 ± 2.8 | 9.59 ± 4.4 | 7.10 |
| 0.12 |
| WASO% | 16.5 ± 12 | 19.9 ± 11 | 1.22 | 0.28 | 0.02 |
| N1 (% TST) | 8.6 ± 3.7 | 8.86 ± 5.2 | 0.059 | 0.81 | < 0.01 |
| N2 (% TST) | 50.3 ± 7.2 | 52.0 ± 6.0 | 0.91 | 0.35 | 0.02 |
| N3 (% TST) | 22.9 ± 6.1 | 22.6 ± 7.3 | 0.024 | 0.88 | < 0.01 |
| REM (% TST) | 18.3 ± 4.8 | 16.6 ± 3.9 | 1.95 | 0.17 | 0.04 |
| Apnea-hypopnea index (AHI) | 19.6 ± 13 | 19.8 ± 12 | NA | 0.83 | NA |
HC, Healthy Controls; BC, breast cancer patients; PSQI, Pittsburgh Sleep Quality Index; ISI, Insomnia Severity Index; WASO, Wake After Sleep Onset; TST, Total sleep time; REM, Rapid-Eye-Movement sleep. P-values < 0.05 are in bold. Effects size: Small (η2 ≥ 0.01), medium (η2 ≥ 0.06), and large (η2 ≥ 0.14). Comparison of the PSQI and the AHI scores were realized with Wilcoxon tests and ISI score with the student’s t.test. Comparison of the sleep architecture was realized with analyses of co-variance with AHI as covariate.
Sleep spindles features during N2 + N3, and slow waves features during N3 (mean ± SD).
| Parameters | HC ( | BC ( | ||
| Spindles (N2 + N3) | Frequency (Hz) | 13.6 ± 0.6 | 13.9 ± 0.5 |
|
| Maximum amplitude (μV) | 10.0 ± 2.5 | 9.57 ± 2.7 | 0.41 | |
| Density (number per epoch) | 2.81 ± 0.9 | 2.79 ± 1.4 | 0.55 | |
| Slow waves (N3) | Peak to peak amplitude (μV) | 80.4 ± 17 | 72.6 ± 20 |
|
| Density (number per epoch) | 9.01 ± 3.6 | 7.95 ± 3.9 | 0.13 | |
HC, Healthy Controls; BC, breast cancer patients. P-values < 0.05 are in bold. Analyses were realized with Wilcoxon tests.
Prospective memory (PM) performances during the wake and sleep sessions (mean ± SD) and analyses of the group and session effects.
| HC ( | BC ( | Group effect | Session effect | Group effect (accounting for wake session performance) | |||||||
| Wake | Sleep | Wake | Sleep |
|
|
| η2 | ||||
|
| 30.0 ± 7.7 | 34.8 ± 8.0 | 26.6 ± 10 | 32.2 ± 11 | 1.48 | 0.23 | 21.5 |
| 0.05 | 0.83 | < 0.01 |
|
| |||||||||||
| EB (/36) | 22.4 ± 6.2 | 25.5 ± 6.3 | 20.2 ± 7.8 | 24.3 ± 7.1 | 1.07 | 0.31 | 14.0 |
| 0.02 | 0.89 | < 0.01 |
| TB (/18) | 7.52 ± 3.0 | 9.24 ± 4.6 | 6.45 ± 4.6 | 7.88 ± 5.0 | 1.27 | 0.27 | 6.21 |
| 0.36 | 0.55 | < 0.01 |
|
| |||||||||||
| Prospective | 8.86 ± 3.2 | 10.7 ± 3.6 | 8.36 ± 3.5 | 9.56 ± 3.6 | 0.96 | 0.33 | 9.37 |
| 1.03 | 0.32 | < 0.01 |
| Retrospective | 12.81 ± 2.7 | 13.8 ± 3.1 | 11.3 ± 4.1 | 13.5 ± 3.5 | 1.04 | 0.31 | 15.1 |
| 0.30 | 0.59 | < 0.01 |
| Associative | 8.29 ± 3.4 | 10.3 ± 2.8 | 7.00 ± 3.9 | 9.06 ± 4.3 | 1.77 | 0.19 | 19.1 |
| 0.25 | 0.62 | < 0.01 |
HC, healthy controls; EB, event-based; P-values < 0.05 are in bold. TB, time-based. Analyses of variance were used for the group and session effect. Analyses of co-variance were used with performance during the wake session as co-variate for the group effect (accounting for wake session performance).